Cotización Satellos Bioscience - MSCL

	Precios en Tiempo Real	Nivel 2
Forex

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

0.73

Postura de Compra

0.72

Postura de Venta

0.78

Volume Operado de la Acción

50,207

0.72 Rango del Día 0.78

0.38 Rango de 52 semanas 0.90

Capitalización de Mercado [m]

82.338M

Precio Anterior

0.75

Precio de Apertura

0.76

Hora

2500

0.73

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

134,066

Acciones en circulación

112,792,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-5.18

Beneficio por acción (BPA)

-0.14

turnover

Beneficio neto

-15.89M

Sector

Coml Physical, Biologcl Resh

Industria

Pharmaceutical Preparations

Sitio web

www.satellos.com

Sede

Toronto, Ontario, Can

Fundado

2007

Satellos Bioscience Inc is listed in the Coml Physical, Biologcl Resh sector of the Toronto Stock Exchange with ticker MSCL. The last closing price for Satellos Bioscience was $0.75. Over the last year, Satellos Bioscience shares have traded in a share price range of $ 0.38 to $ 0.90.

Satellos Bioscience currently has 112,792,000 shares in issue. The market capitalisation of Satellos Bioscience is $84.59 million. Satellos Bioscience has a price to earnings ratio (PE ratio) of -5.18.

Satellos Appoints Stephanie Brown to Board of Directors

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...

Satellos to Participate in November 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.09	-10.9756097561	0.82	0.82	0.67	158631	0.77031909	CS
4	-0.11	-13.0952380952	0.84	0.9	0.67	118649	0.8195762	CS
12	0.19	35.1851851852	0.54	0.9	0.45	134066	0.69001167	CS
26	0.22	43.137254902	0.51	0.9	0.45	94076	0.63332601	CS
52	0.11	17.7419354839	0.62	0.9	0.38	83545	0.61095631	CS
156	0.11	17.7419354839	0.62	0.9	0.38	83545	0.61095631	CS
260	0.11	17.7419354839	0.62	0.9	0.38	83545	0.61095631	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
IVQInvesque Inc	$ 0.15 (50.00%)	12.4k
BRYBri Chem Corp	$ 0.25 (38.89%)	34k
IVQ.UInvesque Inc	US$ 0.095 (18.75%)	14k
PPRPrairie Provident Resources Inc	$ 0.035 (16.67%)	347.09k
GURUGURU Organic Energy Corp	$ 1.83 (16.56%)	40.63k
BUBurcon NutraScience Corporation	$ 0.13 (-35.00%)	1.24M
VRTSVertiqal Studios Corporation	$ 0.01 (-33.33%)	167.01k
NCFNorthcliff Resources Ltd	$ 0.03 (-25.00%)	44.29k
DIAMStar Diamond Corporation	$ 0.03 (-14.29%)	42.86k
EXROExro Technologies Inc	$ 0.16 (-13.51%)	448.9k
CNQCanadian Natural Resources Ltd	$ 46.69 (-1.89%)	22.45M
SUSuncor Energy Inc	$ 55.64 (-2.27%)	19.29M
CVECenovus Energy Inc	$ 21.80 (-1.71%)	7.4M
GWOGreat West Lifeco Inc	$ 50.08 (-0.28%)	6.19M
BTEBaytex Energy Corp	$ 3.97 (-2.22%)	5.6M